ZELSUVMI: Pioneering At-Home Treatment for Molluscum Contagiosum

The Food and Drug Administration (FDA) authorized the topical gel Zelsuvmi on Jan-uary 5, 2024, to treat molluscum contagiosum in children and adults over the age of one. This is the first licensed prescription medication for this highly infectious viral skin illness, primarily af-fecting youngsters. Zelsuvmi produces nitric oxide, which has antiviral properties. The specific treatment method is unclear, but it is believed to involve processes affecting inflammation, immu-nological control, and viral replication. Clinical studies have shown Zelsuvmi to significantly de-crease the number of lesions and be easily tolerated when applied daily. Clinical trials in Phase 3, such as B-SIMPLE 4 and B-SIMPLE 2, were the basis for the FDA's clearance of Zelsuvmi. The treatment is given topically once daily for a maximum duration of 12 weeks. The product is sup-plied in two separate tubes: one contains berdazimer gel and the other contains hydrogel. The most common negative effects of Zelsuvmi are usually experienced in the applied area, such as distress-ing burning, itching, redness, and irritation. Zelsuvmi is anticipated to be commercially accessible in the United States by late 2024, broadening the spectrum of treatment choices for molluscum contagiosum.